BioNTech holder to sell $89.1M in ADS under Rule 144

Medine GmbH filed to resell up to 858,209 BioNTech ADS under Rule 144, with an indicated value near $89.1 million.

Rhea-AI Filing Summary

BioNTech SE (BNTX) received a Rule 144 notice that Medine GmbH intends to sell up to 858,209 American Depositary Shares representing ordinary shares, to be sold through Berenberg Capital Markets LLC. The filing lists an aggregate market value of $89,090,676.29 for these securities and notes that BioNTech had 251,204,366 shares outstanding.

Key Figures

ADS to be sold: 858,209 American Depositary Shares Aggregate market value: $89,090,676.29 Shares outstanding: 251,204,366 shares +2 more

5 metrics

ADS to be sold 858,209 American Depositary Shares Maximum number of BioNTech ADS covered by the Rule 144 notice for Medine GmbH

Aggregate market value $89,090,676.29 Aggregate market value of the 858,209 ADS to be sold

Shares outstanding 251,204,366 shares BioNTech SE shares outstanding as stated in the Form 144

Stock option exercise shares 856,186 ordinary shares Ordinary shares from a stock option exercise on November 21, 2022

Approximate sale date September 3, 2026 Approximate date of sale for the ADS listed in the notice

Key Terms

Rule 144, American Depositary Shares, aggregate market value, Stock Option Exercise, +1 more

5 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

American Depositary Shares financial

"American Depositary Shares representing ordinary shares, no par value per share"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

aggregate market value financial

"858209 | 89090676.29 | 251204366"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Stock Option Exercise financial

"11/21/2022 | Stock Option Exercise | BioNTech SE"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

Nasdaq Global Select market

"09/03/2026 | Nasdaq Global Select"

A Nasdaq Global Select listing is the highest-quality tier on the Nasdaq stock exchange, awarded to companies that meet the strictest financial, reporting and governance standards. Think of it as a “premium shelf” in a store: it signals stronger oversight, transparency and liquidity compared with lower tiers, which helps investors judge company reliability, compare risk, and may attract more institutional buyers.

FAQ

What does the Form 144 filing mean for BioNTech (BNTX)?

The Form 144 states that Medine GmbH plans to sell up to 858,209 BioNTech ADS under Rule 144. This is a proposed resale by an existing holder and does not itself represent a new issuance of shares by BioNTech SE.

How many BioNTech (BNTX) shares are covered by this Rule 144 notice?

The notice covers up to 858,209 American Depositary Shares of BioNTech SE to be sold for the account of Medine GmbH. These ADS represent ordinary shares with no par value per share.

What is the aggregate market value of the BioNTech (BNTX) shares in this Form 144?

The filing lists an aggregate market value of $89,090,676.29 for the 858,209 BioNTech ADS proposed to be sold under Rule 144 for the account of Medine GmbH.

How many BioNTech (BNTX) shares were outstanding according to this filing?

The Form 144 states that BioNTech SE had 251,204,366 shares outstanding. This figure provides context for the size of the 858,209 ADS resale relative to the total outstanding shares.

Who is the broker for the BioNTech (BNTX) Rule 144 sale by Medine GmbH?

The filing identifies Berenberg Capital Markets LLC as the broker for the planned sale of 858,209 BioNTech ADS under Rule 144, with the securities listed on the Nasdaq Global Select market.

What transactions generated the BioNTech (BNTX) shares to be sold?

The notice links the ordinary shares underlying the ADS to stock option exercises on November 21, 2022 and August 9, 2024 involving BioNTech SE ordinary shares with no par value per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 08:04 AM Accepted by SEC EDGAR 09/03/2026 - 08:03 AM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001803150
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	BioNTech SE
SEC File Number	001-39081
Address of Issuer	AN DER GOLDGRUBE 12 MAINZ GERMANY 55131
Phone	0049613190840
Name of Person for Whose Account the Securities are To Be Sold	Medine GmbH
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	10% Stockholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares representing ordinary shares, no par value per share	Berenberg Capital Markets LLC 1251 Avenue of the Americas 53rd Floor New York NY 10020	858209	89090676.29	251204366	09/03/2026	Nasdaq Global Select

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary Shares, no par value per share	11/21/2022	Stock Option Exercise	BioNTech SE			856186	11/21/2022	Stock Option Exercise
Ordinary Shares, no par value per share	08/09/2024	Stock Option Exercise	BioNTech SE			2023	08/09/2024	Stock Option Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The filing of this Form 144 shall not be construed as an admission that the undersigned is an affiliate of the issuer.
Date of Notice	09/03/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Ugur Sahin
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)